APA (7th ed.) Citation

MS, S., OY, S., & MV, S. (2022). [Sub-analyses of the DAPA-CKD study: New data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease]. Terapevticheskii arkhiv, 94(10), 1188. https://doi.org/10.26442/00403660.2022.10.201883

Chicago Style (17th ed.) Citation

MS, Shamkhalova, Sukhareva OY, and Shestakova MV. "[Sub-analyses of the DAPA-CKD Study: New Data on the Use of Sodium-glucose Cotransporter Type 2 Inhibitor in the Treatment of Chronic Kidney Disease]." Terapevticheskii Arkhiv 94, no. 10 (2022): 1188. https://doi.org/10.26442/00403660.2022.10.201883.

MLA (9th ed.) Citation

MS, Shamkhalova, et al. "[Sub-analyses of the DAPA-CKD Study: New Data on the Use of Sodium-glucose Cotransporter Type 2 Inhibitor in the Treatment of Chronic Kidney Disease]." Terapevticheskii Arkhiv, vol. 94, no. 10, 2022, p. 1188, https://doi.org/10.26442/00403660.2022.10.201883.